Herbert Harris, M.D., Ph.D.
Executive Vice President, Translational Medicine
Herbert Harris joined Tonix in 2009 and currently serves as the Executive Vice President of Translational Medicine. Dr. Harris has over 25 years of experience in the fields of drug discovery and development as a psychiatrist, researcher, and medical advisor for several life science companies and government agencies.
Dr. Harris previously held leadership positions as a medical advisor for companies such as Rho, Validus Pharmaceuticals, Jazz Pharmaceuticals, Glaxo SmithKline, and Vela Pharmaceuticals. Dr. Harris also served as the scientific liaison to the Neuropharmacology Division of the U.S. Food and Drug Administration. Prior to his experience in the life science industry, Dr. Harris served as Chief of the Geriatric Psychopharmacology Program and Chief of the Adult Psychopathology Branch at the National Institute of Mental Health. After the completion of his clinical training, Dr. Harris served as Senior Staff Fellow at the National Institute on Aging, a division of the NIH, where his research focused on the mechanisms of programmed cell death in neurons. Dr. Harris completed his residency training in psychiatry at Yale University. He performed postdoctoral research on the neurobiology of addiction in the laboratory of Dr. Eric Nestler, M.D., Ph.D.
Dr. Harris earned his M.D. and Ph.D. degrees from the University of Pittsburgh where his work in immunology involved the immunogenetics and cell biology of Class I MHC antigens through cytokines.